Insmed Incorporated

365 articles with Insmed Incorporated

• taiba Middle East FZ LLC Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE® in the Countries of GCC (Kingdom of Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain).

  6/14/2021

  taiba Middle East announces that Insmed Netherlands BV, a subsidiary of Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, has granted taiba exclusive rights to market and distribute ARIKAYCE® in the Countries of Gulf Cooperation Council.

• Celsion Appoints Christine A. Pellizzari to its Board of Directors

  6/9/2021

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 04, 2021

  6/4/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

• Insmed To Present at Two June 2021 Conferences

  5/25/2021

  Insmed Incorporated Inc., a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that management will present at the following virtual investor events:

• Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference

  5/19/2021

  Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease

• Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

  5/11/2021

  Insmed Incorporated announced that it priced a registered underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and a registered underwritten public offering of $500 million aggregate principal amount of its 0.75% convertible senior notes due 2028.

• Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028

  5/10/2021

  Insmed Incorporated announced that it intends to offer and sell $250 million of its common stock and $500 million aggregate principal amount of its convertible senior notes due 2028 in separate concurrent underwritten public offerings, a portion of which will be used to repurchase Insmed's existing outstanding convertible senior notes due 2025.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 07, 2021

  5/7/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to nine new employees.

• Insmed Reports First Quarter 2021 Financial Results and Provides Business Update

  5/6/2021

  --ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--

• Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021

  4/22/2021

   Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021 .

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2021

  4/7/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to eight new employees.

• ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR

  3/23/2021

  First and Only Therapy Approved in Japan, Europe, and United States for This Difficult-To-Treat Condition

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 05, 2021

  3/5/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to seven new employees.

• Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  2/25/2021

  --ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands-- --Frontline Clinical Trial Program of ARIKAYCE® (amikacin liposome inhalation suspension) in Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium avium complex (MAC) Initiated in Q4 2020--

• Insmed to Present at Two March Conferences

  2/24/2021

  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events: The Cowen 41 st Annual Health Care Conference on Wednesday, March 3, 2021

• Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study

  2/16/2021

   Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release topline data from its Phase 1 healthy volunteer trial

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb 05, 2021

  2/5/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 14 new employees.

• Insmed Reports Grants Under NASDAQ Listing Rule 5635(c)(4)

  12/4/2020

   Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensa

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nov 06, 2020

  11/6/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 10 new employees.

• Insmed to Present at Two November 2020 Conferences

  11/2/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that management will present at the following virtual investor conferences: